OPK: Q2 2026 revenue rose and losses narrowed, with clinical and partnership progress highlighted
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue grew to $163.5M, with operating and net losses narrowing significantly year-over-year. Clinical pipeline advanced with multiple Phase 1 trials, and strategic partnerships expanded, notably in China and with Entera Bio.Original document: Opko Health, Inc. [OPK] SEC 8-K Current Report — Jul. 27 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue grew to $163.5M, with operating and net losses narrowing significantly year-over-year. Clinical pipeline advanced with multiple Phase 1 trials, and strategic partnerships expanded, notably in China and with Entera Bio.
Original document: Opko Health, Inc. [OPK] SEC 8-K Current Report — Jul. 27 2026